The review found no eligible studies for this question.
N‐acetylcysteine showed no clear difference in non‐serious adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
N‐acetylcysteine showed no clear difference in all‐cause mortality compared with placebo (low certainty).
N‐acetylcysteine showed no clear difference in serious adverse events compared with placebo (low certainty).
N‐acetylcysteine showed no clear difference in liver Transplant compared with placebo (low certainty).
TACE followed by 3‐DCRT may leads to lower all‐cause mortality: at 3 years compared with TACE (low certainty).
TACE followed by 3‐DCRT may leads to lower proportion of participants without tumour response (CR+PR) compared with TACE (low certainty).
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).
It is very uncertain whether TACE followed by 3‐DCRT changes proportion of participants without serum AFP normalisation compared with TACE (very low certainty).
It is very uncertain whether methionine and supportive treatment changes mortality compared with supportive treatment (very low certainty).
It is very uncertain whether standard intravenous acetylcysteine regimen (20.5 hour) changes hepatotoxicity compared with shorter intravenous acetylcysteine regimen (12 hour) (very low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics from 0‐2 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower vomiting, retching, or antiemetics 0‐12 hours compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).
Standard intravenous acetylcysteine regimen (20.5 hour) may leads to lower anaphylactoid symptoms compared with shorter intravenous acetylcysteine regimen (12 hour) (low certainty).